LI Linkang,Deputy Director of the National Collaboration Network of Rare Diseases Diagnosis and Treatment.
Deputy Director and Office Director of the National Health Commission's Disease Diagnosis and Protection Experts.
Vice President of the Chinese Hospital Association.
Executive Director of the China Alliance for Rare Diseases.
13:35 PM-13:55 PM
主旨报告
Keynote Speech
罕见病药物临床研发指导原则的几点思考
Thoughts on the Guideline of the Orphan Drug Clinical Research Development
国家食品药品监督管理局药品审评中心
Center for Drug Evaluation of the National Medical Products Administration
13:55 PM-14:15 PM
主旨报告
Keynote Speech
罕见病药物创新生态构建的思考
Thoughts on the Construction of Rare Disease Ecosystem in China
James XUE,Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Founder, Chairman of the Board, Director and CEO of CANbridge, Vice Director of the China Alliance for Rare Diseases
LI Linkang, Deputy Director of the National Collaboration Network of Rare Diseases Diagnosis and Treatment.
Deputy Director and Office Director of the National Health Commission's Disease Diagnosis and Protection Experts.
Vice President of the Chinese Hospital Association.
Executive Director of the China Alliance for Rare Diseases.
Panelists
国家食品药品监督管理局药品审评中心
Center for Drug Evaluation of the National Medical Products Administration
艾星, 国家食品药品监督管理局药品审评中心化药临床一部主审审评员
AI Xing, Chief Reviewer, Medical Review Department I, Center for Drug Evaluation of the National Medical Products Administration
张爱华, 南京医科大学附属儿童医院副院长
ZHANG Aihua, Vice President, Children's Hospital of Nanjing Medical University
James XUE, Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Founder, Chairman of the Board, Director and CEO of CANbridge, Vice Director of the China Alliance for Rare Diseases
陈智胜(线上), 药明生物首席执行官
Chris CHEN, CEO, WuXi Biologics
15:00 PM-17:00 PM
第二阶段
Phase II
Moderator
刘洋, 中国医药创新促进会项目合作部主任
LIU Yang, Director of Project Co-operation, PHIRDA
15:00 PM-15:20 PM
项目1
Project 1
基因编辑疗法在罕见病领域的发展现状和潜力
The Development and Potential of Gene Editing Therapies for Rare Diseases
袁鹏飞, 博雅辑因首席技术官
YUAN Pengfei,CTO, EdiGene
15:20 PM-15:40 PM
项目2
Project 2
单靶点全球首创新药开发: 通过靶向TSP-1阻断TGF-β激活
Developing Single-Target First-in-Class Treatment through Blocking TGF-β Activation by TSP-1 Technology